Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)

Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)

Objectives To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients. Methods A total of 345 RA patients who were not robust in 2021 were assigned to the improved (“robust 2022,” n = 51) and non‐improved (“pre‐frailty/frailty 2022,” n = ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of rheumatic diseases 2024-01, Vol.27 (1), p.e14946-n/a
Hauptverfasser: Ohashi, Yoshifumi, Takahashi, Nobunori, Sobue, Yasumori, Suzuki, Mochihito, Sato, Ryo, Maeda, Masataka, Terabe, Kenya, Asai, Shuji, Imagama, Shiro
Format: Artikel
Sprache:eng
Schlagworte:
frailty
general physical activity
rheumatoid arthritis
robust
target to treat
treatment enhancement
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 1
container_start_page e14946
container_title International journal of rheumatic diseases
container_volume 27
creator Ohashi, Yoshifumi
Takahashi, Nobunori
Sobue, Yasumori
Suzuki, Mochihito
Sato, Ryo
Maeda, Masataka
Terabe, Kenya
Asai, Shuji
Imagama, Shiro
description Objectives To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients. Methods A total of 345 RA patients who were not robust in 2021 were assigned to the improved (“robust 2022,” n = 51) and non‐improved (“pre‐frailty/frailty 2022,” n = 294) groups. Factors associated with “robust 2022” were examined by logistic regression analysis. Patients were assigned to the stable (Follow‐up mean DAS28‐ESR in 2020 and 2021 
doi_str_mv 10.1111/1756-185X.14946
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2891755756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2891755756</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3386-8e1f834b106176cc75c69c0861d22d127fd85d9802d60a1ff9ea8b7120ef85f3</originalsourceid><addsrcrecordid>eNqFkbFuFDEQhi0EIiFQ0yGXobjE3r31eulWEQlIJ4HQSdBZXntMjLzrw_Yeuo5H4BEoeQ4ehSdhLheuxY2tmW9-ef6fkOecXXA8l7xtxILL5tMFX3ZL8YCcHisPj-8lPyFPcv7CmOC1aB-Tk7rtsNWwU_LrI4Tw5_sPE6eSYghgqfUZdAaqTfFbX3b0my-31Kb5My0JdBlhKlgLgU6xUD9uUtwCLbdAXdI-4EAuusyZRkc_9HSji8eJTEukKQ5zLnd9eEX73z_HORRvsA2JxiFD2iIdJx2Qme2Onq_xb9er_ublU_LI6ZDh2f19RtbXr9dXbxardzdvr_rVwtS1FAsJ3Ml6OXDctRXGtI0RnWFScFtVllets7KxnWSVFUxz5zrQcmh5xcDJxtVn5Pwgi1t9nSEXNfps0CM9QZyzqmSHrjboHqKXB9SkmHMCpzbJjzrtFGdqn47a-6_2Wai7dHDixb34PIxgj_y_OBBoDgDaC7v_6an-_eog_BdINJ_j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891755756</pqid></control><display><type>article</type><title>Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ohashi, Yoshifumi ; Takahashi, Nobunori ; Sobue, Yasumori ; Suzuki, Mochihito ; Sato, Ryo ; Maeda, Masataka ; Terabe, Kenya ; Asai, Shuji ; Imagama, Shiro</creator><creatorcontrib>Ohashi, Yoshifumi ; Takahashi, Nobunori ; Sobue, Yasumori ; Suzuki, Mochihito ; Sato, Ryo ; Maeda, Masataka ; Terabe, Kenya ; Asai, Shuji ; Imagama, Shiro</creatorcontrib><description>Objectives To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients. Methods A total of 345 RA patients who were not robust in 2021 were assigned to the improved (“robust 2022,” n = 51) and non‐improved (“pre‐frailty/frailty 2022,” n = 294) groups. Factors associated with “robust 2022” were examined by logistic regression analysis. Patients were assigned to the stable (Follow‐up mean DAS28‐ESR in 2020 and 2021 &lt; 3.2, n = 225) and unstable (≥3.2, n = 120) groups, which were further divided into the non‐improved (stable: n = 180, unstable: n = 114) and improved (stable: n = 45, unstable: n = 6) groups. Factors influencing Japanese Cardiovascular Health Study (J‐CHS) score were examined by multiple regression analysis. Changes over 2 years were compared between the non‐improved and improved groups of the stable group. Results The associated factor of “robust 2022” was the follow‐up meanDAS28‐ESR in 2020 and 2021 &lt; 3.2 (i.e., stable state) (OR: 4.01). Follow‐up mean DAS28‐ESR in 2020 and 2021 was associated with J‐CHS score (T = 2.536, p = .013) only in the unstable group. In the stable group, HAQ‐DI was lower (2020: 0.32 vs. 0.16; 2021: 0.32 vs. 0.17; 2022: 0.32 vs. 0.21), and the proportion of J‐CHS: Q4 (weakness) was lower (2020: 48.4 vs. 17.8%; 2021: 55.0 vs. 29.2%; 2022: 50.4 vs. 0%), in the improved group than in the non‐improved group, whereas both groups maintained clinical and functional remission over 2 years. Conclusions Drug treatment to maintain well‐controlled disease activity alone is insufficient for improving patients' frailty status after achieving treat‐to‐target goals, suggesting the need for multifaceted approaches.</description><identifier>ISSN: 1756-1841</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.14946</identifier><identifier>PMID: 37975650</identifier><language>eng</language><publisher>England</publisher><subject>frailty ; general physical activity ; rheumatoid arthritis ; robust ; target to treat ; treatment enhancement</subject><ispartof>International journal of rheumatic diseases, 2024-01, Vol.27 (1), p.e14946-n/a</ispartof><rights>2023 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3386-8e1f834b106176cc75c69c0861d22d127fd85d9802d60a1ff9ea8b7120ef85f3</cites><orcidid>0000-0001-6937-3567 ; 0000-0002-7521-6928 ; 0000-0001-6469-1312 ; 0000-0002-4030-8793 ; 0000-0002-8936-4278</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1756-185X.14946$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1756-185X.14946$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37975650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohashi, Yoshifumi</creatorcontrib><creatorcontrib>Takahashi, Nobunori</creatorcontrib><creatorcontrib>Sobue, Yasumori</creatorcontrib><creatorcontrib>Suzuki, Mochihito</creatorcontrib><creatorcontrib>Sato, Ryo</creatorcontrib><creatorcontrib>Maeda, Masataka</creatorcontrib><creatorcontrib>Terabe, Kenya</creatorcontrib><creatorcontrib>Asai, Shuji</creatorcontrib><creatorcontrib>Imagama, Shiro</creatorcontrib><title>Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Objectives To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients. Methods A total of 345 RA patients who were not robust in 2021 were assigned to the improved (“robust 2022,” n = 51) and non‐improved (“pre‐frailty/frailty 2022,” n = 294) groups. Factors associated with “robust 2022” were examined by logistic regression analysis. Patients were assigned to the stable (Follow‐up mean DAS28‐ESR in 2020 and 2021 &lt; 3.2, n = 225) and unstable (≥3.2, n = 120) groups, which were further divided into the non‐improved (stable: n = 180, unstable: n = 114) and improved (stable: n = 45, unstable: n = 6) groups. Factors influencing Japanese Cardiovascular Health Study (J‐CHS) score were examined by multiple regression analysis. Changes over 2 years were compared between the non‐improved and improved groups of the stable group. Results The associated factor of “robust 2022” was the follow‐up meanDAS28‐ESR in 2020 and 2021 &lt; 3.2 (i.e., stable state) (OR: 4.01). Follow‐up mean DAS28‐ESR in 2020 and 2021 was associated with J‐CHS score (T = 2.536, p = .013) only in the unstable group. In the stable group, HAQ‐DI was lower (2020: 0.32 vs. 0.16; 2021: 0.32 vs. 0.17; 2022: 0.32 vs. 0.21), and the proportion of J‐CHS: Q4 (weakness) was lower (2020: 48.4 vs. 17.8%; 2021: 55.0 vs. 29.2%; 2022: 50.4 vs. 0%), in the improved group than in the non‐improved group, whereas both groups maintained clinical and functional remission over 2 years. Conclusions Drug treatment to maintain well‐controlled disease activity alone is insufficient for improving patients' frailty status after achieving treat‐to‐target goals, suggesting the need for multifaceted approaches.</description><subject>frailty</subject><subject>general physical activity</subject><subject>rheumatoid arthritis</subject><subject>robust</subject><subject>target to treat</subject><subject>treatment enhancement</subject><issn>1756-1841</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkbFuFDEQhi0EIiFQ0yGXobjE3r31eulWEQlIJ4HQSdBZXntMjLzrw_Yeuo5H4BEoeQ4ehSdhLheuxY2tmW9-ef6fkOecXXA8l7xtxILL5tMFX3ZL8YCcHisPj-8lPyFPcv7CmOC1aB-Tk7rtsNWwU_LrI4Tw5_sPE6eSYghgqfUZdAaqTfFbX3b0my-31Kb5My0JdBlhKlgLgU6xUD9uUtwCLbdAXdI-4EAuusyZRkc_9HSji8eJTEukKQ5zLnd9eEX73z_HORRvsA2JxiFD2iIdJx2Qme2Onq_xb9er_ublU_LI6ZDh2f19RtbXr9dXbxardzdvr_rVwtS1FAsJ3Ml6OXDctRXGtI0RnWFScFtVllets7KxnWSVFUxz5zrQcmh5xcDJxtVn5Pwgi1t9nSEXNfps0CM9QZyzqmSHrjboHqKXB9SkmHMCpzbJjzrtFGdqn47a-6_2Wai7dHDixb34PIxgj_y_OBBoDgDaC7v_6an-_eog_BdINJ_j</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Ohashi, Yoshifumi</creator><creator>Takahashi, Nobunori</creator><creator>Sobue, Yasumori</creator><creator>Suzuki, Mochihito</creator><creator>Sato, Ryo</creator><creator>Maeda, Masataka</creator><creator>Terabe, Kenya</creator><creator>Asai, Shuji</creator><creator>Imagama, Shiro</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6937-3567</orcidid><orcidid>https://orcid.org/0000-0002-7521-6928</orcidid><orcidid>https://orcid.org/0000-0001-6469-1312</orcidid><orcidid>https://orcid.org/0000-0002-4030-8793</orcidid><orcidid>https://orcid.org/0000-0002-8936-4278</orcidid></search><sort><creationdate>202401</creationdate><title>Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)</title><author>Ohashi, Yoshifumi ; Takahashi, Nobunori ; Sobue, Yasumori ; Suzuki, Mochihito ; Sato, Ryo ; Maeda, Masataka ; Terabe, Kenya ; Asai, Shuji ; Imagama, Shiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3386-8e1f834b106176cc75c69c0861d22d127fd85d9802d60a1ff9ea8b7120ef85f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>frailty</topic><topic>general physical activity</topic><topic>rheumatoid arthritis</topic><topic>robust</topic><topic>target to treat</topic><topic>treatment enhancement</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohashi, Yoshifumi</creatorcontrib><creatorcontrib>Takahashi, Nobunori</creatorcontrib><creatorcontrib>Sobue, Yasumori</creatorcontrib><creatorcontrib>Suzuki, Mochihito</creatorcontrib><creatorcontrib>Sato, Ryo</creatorcontrib><creatorcontrib>Maeda, Masataka</creatorcontrib><creatorcontrib>Terabe, Kenya</creatorcontrib><creatorcontrib>Asai, Shuji</creatorcontrib><creatorcontrib>Imagama, Shiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohashi, Yoshifumi</au><au>Takahashi, Nobunori</au><au>Sobue, Yasumori</au><au>Suzuki, Mochihito</au><au>Sato, Ryo</au><au>Maeda, Masataka</au><au>Terabe, Kenya</au><au>Asai, Shuji</au><au>Imagama, Shiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2024-01</date><risdate>2024</risdate><volume>27</volume><issue>1</issue><spage>e14946</spage><epage>n/a</epage><pages>e14946-n/a</pages><issn>1756-1841</issn><eissn>1756-185X</eissn><abstract>Objectives To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients. Methods A total of 345 RA patients who were not robust in 2021 were assigned to the improved (“robust 2022,” n = 51) and non‐improved (“pre‐frailty/frailty 2022,” n = 294) groups. Factors associated with “robust 2022” were examined by logistic regression analysis. Patients were assigned to the stable (Follow‐up mean DAS28‐ESR in 2020 and 2021 &lt; 3.2, n = 225) and unstable (≥3.2, n = 120) groups, which were further divided into the non‐improved (stable: n = 180, unstable: n = 114) and improved (stable: n = 45, unstable: n = 6) groups. Factors influencing Japanese Cardiovascular Health Study (J‐CHS) score were examined by multiple regression analysis. Changes over 2 years were compared between the non‐improved and improved groups of the stable group. Results The associated factor of “robust 2022” was the follow‐up meanDAS28‐ESR in 2020 and 2021 &lt; 3.2 (i.e., stable state) (OR: 4.01). Follow‐up mean DAS28‐ESR in 2020 and 2021 was associated with J‐CHS score (T = 2.536, p = .013) only in the unstable group. In the stable group, HAQ‐DI was lower (2020: 0.32 vs. 0.16; 2021: 0.32 vs. 0.17; 2022: 0.32 vs. 0.21), and the proportion of J‐CHS: Q4 (weakness) was lower (2020: 48.4 vs. 17.8%; 2021: 55.0 vs. 29.2%; 2022: 50.4 vs. 0%), in the improved group than in the non‐improved group, whereas both groups maintained clinical and functional remission over 2 years. Conclusions Drug treatment to maintain well‐controlled disease activity alone is insufficient for improving patients' frailty status after achieving treat‐to‐target goals, suggesting the need for multifaceted approaches.</abstract><cop>England</cop><pmid>37975650</pmid><doi>10.1111/1756-185X.14946</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6937-3567</orcidid><orcidid>https://orcid.org/0000-0002-7521-6928</orcidid><orcidid>https://orcid.org/0000-0001-6469-1312</orcidid><orcidid>https://orcid.org/0000-0002-4030-8793</orcidid><orcidid>https://orcid.org/0000-0002-8936-4278</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-1841
ispartof International journal of rheumatic diseases, 2024-01, Vol.27 (1), p.e14946-n/a
issn 1756-1841
1756-185X
language eng
recordid cdi_proquest_miscellaneous_2891755756
source Wiley Online Library Journals Frontfile Complete
subjects frailty
general physical activity
rheumatoid arthritis
robust
target to treat
treatment enhancement
title Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Well%E2%80%90controlled%20disease%20activity%20with%20drug%20treatment%20will%20not%20improve%20the%20frailty%20status%20of%20RA%20patients%20to%20robust%20state:%20A%C2%A0multicenter%20observational%20study%20(T%E2%80%90FLAG)&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Ohashi,%20Yoshifumi&rft.date=2024-01&rft.volume=27&rft.issue=1&rft.spage=e14946&rft.epage=n/a&rft.pages=e14946-n/a&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.14946&rft_dat=%3Cproquest_cross%3E2891755756%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2891755756&rft_id=info:pmid/37975650&rfr_iscdi=true